ArticleFrontiers in cell and developmental biology2026
Bone marrow plasma cytokine composition indicates acute myeloid leukemia progression and treatment response.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The progression of acute myeloid leukemia (AML) is characterized by intricate interactions between leukemia cells and the bone marrow (BM) microenvironment. Methods: In this study, we conducted a comprehensive analysis of the plasma cytokine composition in BM samples from patients with AML. A total of 75 BM samples were collected from AML patients consecutively recruited, including 41 newly diagnosed (ND-AML), 19 complete remission (CR) and 15 relapsed/refractory cases (R/R-AML). Using enzyme-linked immunoadsorbent assay, we analyzed BM plasma levels of interleukin (IL)-1 family (IL-1β, IL-1RA and IL-18), IL-2 family (IL-2, IL-4, IL-13, IL-15 and IL-21), IL-12, interferon-gamma (IFN-γ), innate inflammatory and immune regulatory cytokines [IL-6, IL-10, IL-17, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β]. Results: Our study found significant differences in BM plasma inflammatory and immunologic cytokines between ND-AML, CR, and R/R-AML, with notable changes in LDH, ELN risk, IL-12, IL-18, and IL-21 between incomplete remission (ICR) and CR status. These cytokines were at weakened level in the BM microenvironment of R/R-AML. Concentrations of IL-17 and TGF-β in BM plasma elevated at initial diagnosis, declined after CR, and increased again at relapse, indicating the disease activity. Conclusion: These findings emphasize the dynamic monitoring of BM plasma cytokines during AML progression, and highlight the significance of cytokine composition in guiding treatment and improving patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.